FACULTY INFORMATION & DISCLOSURES
Jeffrey R. Bishop, PharmD, BCPP (Activity Chair)
University of Illinois at Chicago
College of Pharmacy
Dr. Bishop is Assistant Professor of Pharmacy and Psychiatry at the University of Illinois at Chicago (UIC). In this role he conducts psychopharmacology and pharmacogenomics research with a primary focus on antipsychotic drugs in early course schizophrenia and bipolar disorders. Dr. Bishop is a Board Certified Psychiatric Pharmacist and serves as a Clinical Pharmacist and Psychiatry Medical Resident Supervisor in the outpatient Psychosis Clinic. Additionally he is a PGYI and PGYII Pharmacy Resident Research Supervisor and also teaches antipsychotic pharmacology to PharmD, MD, and PhD students and residents at UIC.
Dr. Bishop earned a degree in biology at Luther College and went on to complete his PharmD at the University of Iowa. Subsequently, he completed a fellowship in clinical psychopharmacology and pharmacogenetics at the University of Iowa, College of Pharmacy as well as a Master’s Degree in Clinical Investigation through the University of Iowa, College of Medicine.
Dr. Bishop’s clinical and research interests are primarily devoted to schizophrenia and other psychotic disorders. Currently he is the Principal Investigator of NARSAD and
NIMH-funded studies of antipsychotic pharmacogenomics.
Dr. Bishop has disclosed that he receives grant/research support from Ortho-McNeil Janssen and other financial or material support from Eli Lilly.
Peter J. Weiden, MD
Professor of Psychiatry
Director of the Psychotic Disorders Program
University of Illinois at Chicago Medical Center
Center for Cognitive Medicine
Dr. Weiden is a Professor of Psychiatry and Director of the Psychotic Disorders Program at the Center for Cognitive Medicine at the University of Illinois at Chicago MedicalCenter (UIC). He received his undergraduate degree at Swarthmore College in Swarthmore, Pennsylvania and his MD at SUNY Stony Brook. He completed his psychiatric
residency at Payne Whitney Clinic–New York Hospital in 1985 and a psychiatric epidemiology fellowship at Mailman School of Public Health at Columbia University in 1999.
Dr. Weiden has focused on improving clinical outcomes for patients with schizophrenia. In particular, Dr. Weiden’s research career has focused on bridging psychopharmacology and public health issues in the treatment of schizophrenia. He has published extensively on the problem of medication nonadherence (noncompliance) in schizophreniaand has helped develop some of the current models and measures for nonadherence.
Dr. Weiden was named Exemplary Psychiatrist on three separate occasions by NAMI, in 1995, 1997, and 2000. For his research on relapse prevention, Dr. Weiden receivedNAMI’s Judith Silver Young Scientist Award in 1996. His book, Breakthroughs in Antipsychotic Medications, received the Ken Johnson Memorial Book Award for one of the
most outstanding books in mental health published in 1999.
Dr. Weiden’s current research interests focus on pharmacologic and psychotherapeutic approaches to better address medication adherence problems for persons with schizophrenia.He is studying the effectiveness of early intervention using a combination of long-acting medication route and psychoeducation for “first-episode” schizophrenia
patients. Dr. Weiden is currently testing an adherence intervention based on a CBT model to improve medication effectiveness for patients with “first-episode” schizophreniaand is conducting an NIMH-funded clinical trial evaluating the effectiveness of CBT-oriented vs. psychoeducation focused psychotherapeutic interventions in youngadults who have just begun maintenance medication therapy after an initial psychotic episode.
Dr. Weiden has disclosed that he is consultant for Biovail, Bristol-Myers Squibb, Delpor, Eli Lilly, Endo, Lundbeck, Merck, Novartis, Ortho-McNeil Janssen, Pfizer, Takeda,and Vanda; receives grant/research support from the NIMH, Novartis, Ortho-McNeil Janssen, and Sunovion; and is a member of the speakers’ bureaus for Merck, Novartis,Ortho-McNeil Janssen, and Pfizer.
Kenneth H. Brasfield, PharmD, BCPP
Virginia Commonwealth University
School of Pharmacy
University of Virginia
School of Medicine and Nursing
Dr. Brasfield is the Consultant in Clinical Psychopharmacology for Western State Hospital, Staunton, Virginia. He is also an Assistant Professor at the School of Pharmacy at Virginia Commonwealth University and School of Medicine and Nursing at the University of Virginia. He has been at Western State Hospital since 1988 and practicing clinical psychiatric pharmacy (including residency) since 1979.
Dr. Brasfield rounds with the 11 treatment teams at Western State Hospital on a weekly basis, performs formal and informal clinical psychopharmacological consultations, and participates in and is the group leader in symptom management and patient medication groups. He trains fourth year psychiatry residents, psychiatric nurse practitioner students, medical students, and pharmacy students in clinical psychopharmacology.
He is an active member of Western State Hospital’s Pharmacy and Therapeutics Committee, performs medication regimen and drug utilization evaluation reviews, and provides adverse drug reaction and medication error reports. He also provides scientific reviews and expert opinions that help the medical staff at Western State Hospital establish their standards of care and philosophical approaches for prescribing psychotropic medications.
Dr. Brasfield is an active member of the Behavioral Management Team at Western State Hospital where cases are referred and a holistic review occurs due to continued significant symptom management issues. He serves as the Consultant in Clinical Psychopharmacology for Wall Residencies and Valley Community Services Board.Dr. Brasfield is also a medico-legal expert witness and case reviewer for criminal and civil cases involving the prescribing and/or use of psychotropic medications.
Dr. Brasfield has disclosed that he is a member of the speakers’ bureaus for Janssen Pharmaceuticals and Merck.
The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CE activity.
To receive a statement of credit, you must:
- Review the full content of the activity
- Complete the questions within the activity
- Complete the evaluation at the end of the activity.
The College of Psychiatric and Neurologic Pharmacists (CPNP) and Creative Educational Concepts, Inc. (CEC) are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. This application-based activity will be co-sponsored by CPNP and CEC and has been assigned ACPE #0284-9999-11-040-H01-P and will award 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming.
|Published: July 13, 2011
||Expires: July 13, 2012
This activity is complimentary.
Audio/slides with interactive questions. Printable PDF also available.
Specialty pharmacists who are involved in treating and managing patients with schizophrenia.
Please complete the posttest questions and activity evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.
Please contact us at 859-260-1717 or firstname.lastname@example.org with any questions
Statement of Need/Program Overview
Schizophrenia is a debilitating and emotionally devastating illness with long-term impact on patients’ lives. Medication nonadherence occurs often, and long-acting antipsychotic formulations may be an option for reducing adherence difficulties. While long-acting therapies have traditionally been reserved for treatment-resistant patients, newer research indicates that these formulations may be both accepted and beneficial for patients in the early course of illness.
This engaging, interactive educational session will provide a comprehensive update on long-acting injectable antipsychotic (LAI) agents used in the treatment of schizophrenia and schizoaffective disorder. Our expert speakers will provide an outline of all agents currently FDA-approved for schizophrenia and examine how they may optimally be used. Pros/cons for each agent will be discussed. Research investigating the use of long-acting antipsychotic medications to improve adherence will be presented. In addition, the practical aspects of providing treatment in different clinical environments will be discussed. Panel discussants from a variety of clinical settings will consider the role of the pharmacist in LAI antipsychotic clinics.
At the conclusion of this application-based activity, participants should be able to:
- Compare available long-acting injectable antipsychotic agents with regard to indication/use, pros and cons, pharmacokinetic profile, dosing, and clinical pearls.
- Identify potential benefits of LAI antipsychotics on adherence and clinical outcomes in schizophrenia and schizoaffective disorder.
- Strategize treatment options that employ the appropriate use of long-acting injectable antipsychotics in various settings, including hospitals, community settings,and the Veterans Affairs health system.
It is the policy of CEC and CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.
Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
This activity was originally presented as a LIVE symposium at the 2011 Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP). If you received credit for attending this activity, you are not eligible to receive credit for the online version, but you are welcome to use it as a resource in your practice.
REQUIRED COMPUTER HARDWARE/SOFTWARE:
- Intel Pentium ll 450MHz or faster processor (or equivalent)
- 128MB of RAM
- Microsoft Windows 98, Windows Me, Windows 2000, Windows XP, Windows Server 2003
- Microsoft Internet Explorer 5.5, Firefox l.x, Mozilla l.x, Netscape 7.x or later, AOL 9, Opera 7.11 or later
- PowerPC G3 SOOMI-Iz or faster processor
- 128MB of RAM 4 4
- Mac OS X v.l0.l.x, l0.2.x, l0.3.x, or l0.4.x
- Internet Explorer 5.2, Firefox 1.x, Mozilla l.x, Netscape 7.x or later, AOL for Mac OS X, Opera 6, Safari l.x' or later